March 1, 2023
UCB Japan said on February 28 that it filed a new drug application (NDA) in Japan for its neonatal Fc receptor (FcRn) inhibitor rozanolixizumab for the treatment of adults with generalized myasthenia gravis (gMG) on the same day. The regulatory...read more